http://www.nytimes.com/2016/09/15/arts/design/hudson-yards-own-social-climbing-stairway.html?ref=todayspaper

Buying the Stairway…to Hearing

By Amyn Amlani and Holly Hosford-Dunn There’s a lady who’s sure All that glitters is gold And she’s buying a stairway to…[hearing]. We’re recalling the lyrics to Led Zeppelin’s Stairway to Heaven, as an inspiration for our series of posts on pricing.  In Part 3 of our series of blogs on pricing that commenced in…

Read More

Price Functions in the US Wholesale Hearing Aid Market, part 2

Real Price at retail isn’t rising in general and is actually falling for Premium products.  Something similar but even more dramatic is happening on the wholesale level. So concluded last week’s post and is the jumping off place today.   Average Wholesale Price Functions   Average wholesale Price of hearing aids increased faster than inflation1…

Read More

Price Functions in the US Wholesale Hearing Aid Market

This series now steps into the dark and murky realm of manufacturers’ wholesale pricing of product to see how the market has changed since 2013.  The caveats remain the same:   Big assumptions:  Categorical lines separating Economy, Premium, and everything in between are arbitrary to some extent, reflecting the varying family of products, product-specific technology levels,…

Read More
https://memegenerator.net/instance/54677375

Price Functions in the US Retail Hearing Aid Market, Part 2

by Holly Hosford-Dunn, PhD & Amyn Amlani, PhD   Average Sale Price of hearing aids in the US retail market (ASP) grew at the rate of inflation from 2004-2011, peaked in price in 2012 and declined each year thereafter. At no time has ASP ever hit $6K/set, no matter how many times that anchor price gets…

Read More
https://www.pinterest.com/zambianprincess/the-most-interesting-man-in-the-world-quotes/

Mucking Around with Hearing Aid Price, Again

by Holly Hosford-Dunn, PhD and Amyn Amlani,PhD   The Pricing series revs up for a multi-year update today, just in time to get in on the PCAST and IOM action of recent days and await signs from the FDA.  In 2013, the announced intent was to “dive down and muck around with Price to test…

Read More